Considering the Side Effects of Drugmakers’ Money-Back Guarantees

The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.
By KATIE THOMAS and CHARLES ORNSTEIN from NYT Health http://ift.tt/2u07daw
via IFTTT
Drugs (Pharmaceuticals), Repatha (Drug), Health Insurance and Managed Care
Source The New York Times
Làm đẹp Blog 247